Brief description of study

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a
target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg
twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of
composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event
analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary
congestion, with no known prior history of chronic HF..